ArticleBMJ open2013
Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital.
Article in BMJ open, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Structured Pharmacist Review of Medication in Older Hospitalised Patients: A Cost-Effectiveness Analysis.Drugs & aging · 2016Trial
- Clinical Pharmacist-Led Collaboration of Multiple Clinical Professions Model Focusing on Continuity of Pharmacotherapy: Japanese Version of the Lund Integrated Medicines Management (LIMM) Model.Pharmacy (Basel, Switzerland) · 2024Review
- Article
- A Trial-Based Cost-Utility Analysis of a Medication Optimization Intervention Versus Standard Care in Older Adults.Drugs & aging · 2023Article
- Economic evaluation of a collaborative model of pharmaceutical care in an Irish hospital: cost-utility analysis.HRB open research · 2023Article
- Evaluation of medication reconciliation process in internal medicine wards of an academic medical center by a pharmacist: errors and risk factors.Internal and emergency medicine · 2022Article
- Time distribution for pharmacists conducting a randomized controlled trial-An observational time and motion study.PloS one · 2021Observational
- The effect of a pharmaceutical transitional care program on rehospitalisations in internal medicine patients: an interrupted-time-series study.BMC health services research · 2019Article
- Outcomes and costs of remote patient monitoring among patients with implanted cardiac defibrillators: An economic model based on the PREDICT RM database.Journal of cardiovascular electrophysiology · 2019Observational
- Cost-Effectiveness Analysis of a Physician-Implemented Medication Screening Tool in Older Hospitalised Patients in Ireland.Drugs & aging · 2018Article
- Cost-effectiveness of a transitional pharmaceutical care program for patients discharged from the hospital.PloS one · 2017Article
- Evaluation of a controlled, national collaboration study on a clinical pharmacy service of screening for risk medications.International journal of clinical pharmacy · 2014Article
- End-of-Life Care Interventions: An Economic Analysis.Ontario health technology assessment series · 2014Review
- Medication reconciliation and prescribing reviews by pharmacy technicians in a geriatric ward.Journal of research in pharmacy practice · 2013Article
- Preliminary investigation of economics issues in hospitalized patients with stroke.International journal of preventive medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the cost effectiveness of a multidisciplinary team including a pharmacist for systematic medication review and reconciliation from admission to discharge at hospital among elderly patients (the Lund Integrated Medicines Management (LIMM)) in order to reduce drug-related readmissions and outpatient visits.
methodPublished data from the LIMM project group were used to design a probabilistic decision tree model for evaluating tools for (1) a systematic medication reconciliation and review process at initial hospital admission and during stay (admission part) and (2) a medication report for patients discharged from hospital to primary care (discharge part). The comparator was standard care. Inpatient, outpatient and staff time costs (Euros, 2009) were calculated during a 3-month period. Dis-utilities for hospital readmissions and outpatient visits due to medication errors were taken from the literature.
resultsThe total cost for the LIMM model was €290 compared to €630 for standard care, in spite of a €39 intervention cost. The main cost offset arose from avoided drug-related readmissions in the Admission part (€262) whereas only €66 was offset in the Discharge part as a result of fewer outpatient visits and correction time. The reduced disutility was estimated to 0.005 quality-adjusted life-years (QALY), indicating that LIMM was a dominant alternative. The probability that the intervention would be cost-effective at a zero willingness to pay for a gained QALY compared to standard care was estimated to 98%.
conclusionsThe LIMM medication reconciliation (at admission and discharge) and medication review was both cost-saving and generated greater utility compared to standard care, foremost owing to avoided drug-related hospital readmissions. When implementing such a review process with a multidisciplinary team, it may be important to consider a learning curve in order to capture the full advantage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.